| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial A Rittmeyer, F Barlesi, D Waterkamp, K Park, F Ciardiello, J Von Pawel, ... The Lancet 389 (10066), 255-265, 2017 | 4619 | 2017 |
| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial L Fehrenbacher, A Spira, M Ballinger, M Kowanetz, J Vansteenkiste, ... The Lancet 387 (10030), 1837-1846, 2016 | 2853 | 2016 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 383 | 2020 |
| Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated … L Fehrenbacher, J von Pawel, K Park, A Rittmeyer, DR Gandara, SP Aix, ... Journal of thoracic oncology 13 (8), 1156-1170, 2018 | 242 | 2018 |
| Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic … M Peeters, KS Oliner, TJ Price, A Cervantes, AF Sobrero, M Ducreux, ... Clinical Cancer Research 21 (24), 5469-5479, 2015 | 209 | 2015 |
| Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study DR Gandara, J von Pawel, J Mazieres, R Sullivan, Å Helland, JY Han, ... Journal of Thoracic Oncology 13 (12), 1906-1918, 2018 | 131* | 2018 |
| Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC F Barlesi, K Park, F Ciardiello, J Von Pawel, S Gadgeel, T Hida, ... Annals of Oncology 27, vi581, 2016 | 113 | 2016 |
| Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non–small-cell lung cancer R Bordoni, F Ciardiello, J von Pawel, D Cortinovis, T Karagiannis, ... Clinical Lung Cancer 19 (5), 441-449. e4, 2018 | 72 | 2018 |
| A model of overall survival predicts treatment outcomes with atezolizumab versus chemotherapy in non–small cell lung cancer based on early tumor kinetics L Claret, JY Jin, C Ferté, H Winter, S Girish, M Stroh, P He, M Ballinger, ... Clinical Cancer Research 24 (14), 3292-3298, 2018 | 60 | 2018 |
| Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR) J Vansteenkiste, L Fehrenbacher, AI Spira, J Mazieres, K Park, D Smith, ... European Journal of Cancer 51, S716-S717, 2015 | 50 | 2015 |
| Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein … QF Yin, SH Fu, P He, Y Xiong Atherosclerosis 190 (1), 53-61, 2007 | 40 | 2007 |
| Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein CW Lu, Y Xiong, P He Nitric Oxide 16 (1), 94-103, 2007 | 36 | 2007 |
| Futility stopping in clinical trials P He, TL Lai, OY Liao Statistics and its interface 5, 415-423, 2012 | 35 | 2012 |
| LBA42 COAST: an open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage … A Martinez-Marti, M Majem, F Barlesi, EC Costa, Q Chu, I Monnet, ... Annals of Oncology 32, S1320, 2021 | 32 | 2021 |
| Very high-risk localized prostate cancer: outcomes following definitive radiation AK Narang, C Gergis, SP Robertson, P He, AN Ram, TR McNutt, E Griffith, ... International Journal of Radiation Oncology* Biology* Physics 94 (2), 254-262, 2016 | 32 | 2016 |
| Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). DA Smith, JF Vansteenkiste, L Fehrenbacher, K Park, J Mazieres, ... Journal of Clinical Oncology 34 (15_suppl), 9028-9028, 2016 | 31 | 2016 |
| PL04a. 02: OAK, a randomized Ph III study of atezolizumab vs docetaxel in patients with advanced NSCLC: results from subgroup analyses S Gadgeel, F Ciardiello, A Rittmeyer, F Barlesi, D Cortinovis, C Barrios, ... Journal of Thoracic Oncology 12 (1), S9-S10, 2017 | 26 | 2017 |
| A sequential testing approach to detecting multiple change points in the proportional hazards model P He, L Fang, Z Su Statistics in Medicine, 2012 | 21 | 2012 |
| Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR. J Mazieres, L Fehrenbacher, A Rittmeyer, AI Spira, K Park, DA Smith, ... Journal of Clinical Oncology 34 (15_suppl), 9032-9032, 2016 | 20 | 2016 |
| 697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable … TB Powles, MS Van Der Heijden, DC Gauna, Y Loriot, MD Galsky, ... Annals of Oncology 31, S550-S551, 2020 | 19 | 2020 |
